The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

✍ Scribed by Rosella Silvestrini; Maria Grazia Daidone; Silvia Veneroni; Elvira Benini; Giovanna Scarfone; Flavia Zanaboni; Antonella Villa; Mauro Presti; Saverio Danese; Giorgio Bolis

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 110 KB
• Volume: 82
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19980101)82:1<159::aid-cncr20>3.0.co;2-0

✦ Synopsis

GST-p were generally unrelated to one another and unrelated to clinicopathologic features, except for an association between DNA ploidy and the rate of cell prolifer-1 Oncologia Sperimentale C, Istituto Nazionale ation. All biologic variables except bcl-2 were slightly related to tumor grade. DNA per lo Studio e la Cura dei Tumori, Milan, Italy.

ploidy emerged as a predictor of clinical complete response and 3-year overall 2 Chirurgia Ginecologica, Istituto Nazionale per survival, regardless of treatment type or residual disease. Conversely, except for a lo Studio e la Cura dei Tumori, Milan, Italy.

favorable outcome for patients with tumors not expressing bcl-2 who were treated